[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Liu YL, Tsai SH, Chang FW, Yu MH: Ifosfamide-induced encephalopathy in patients with uterine sarcoma. Taiwan J Obstet Gynecol; 2010 Mar;49(1):77-80
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
  • OBJECTIVE: To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management.
  • CASE REPORTS: The patient in the first case developed grade 4 toxicity and had a partial response after the fourth dose of intravenous methylene blue was administered.
  • CONCLUSION: Careful evaluation of patients with recurrent gynecologic cancers and vigilance during infusion of chemotherapeutic regimens are important in reducing the risk and timely management of IIE.
  • Both methylene blue and thiamine appear to be effective treatments for IIE.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Ifosfamide / adverse effects. Neurotoxicity Syndromes / etiology. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Aged. Female. Humans. Methylene Blue / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Thiamine / therapeutic use. Vitamin B Complex / therapeutic use

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. Vitamin B1 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20466298.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 12001-76-2 / Vitamin B Complex; T42P99266K / Methylene Blue; UM20QQM95Y / Ifosfamide; X66NSO3N35 / Thiamine
  •  go-up   go-down


2. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ: Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res; 2010 Feb 15;16(4):1298-306
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study assessed the safety/tolerability, pharmacokinetics, and clinical activity of three times weekly i.v.
  • EXPERIMENTAL DESIGN: Patients with stage IB2 to IVB cervical cancer (n = 10) or recurrent uterine sarcoma (n = 1) were assigned to dose-finding cohorts of 2-hour 3-AP infusions during 5 weeks of cisplatin chemoradiation.
  • RESULTS: The maximum tolerated 3-AP dose was 25 mg/m(2) given three times weekly during cisplatin and pelvic radiation.
  • CONCLUSIONS: 3-AP was well tolerated at a three times weekly i.v.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):223-9 [12203104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):637-42 [11849784.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):277-85 [12967138.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4092-100 [14519631.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):1-6 [14729598.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(3):285-92 [14755613.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1553-63 [15117978.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 1;1699(1-2):1-34 [15158709.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):331-42 [15148626.001]
  • [Cites] J Biol Chem. 1970 Oct 25;245(20):5228-33 [4319235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):317-22 [110744.001]
  • [Cites] Clin Chem. 1980 Aug;26(9):1304-8 [6772341.001]
  • [Cites] Life Sci. 1981 Mar 2;28(9):1007-14 [7012518.001]
  • [Cites] Ann Clin Lab Sci. 1989 Sep-Oct;19(5):383-8 [2802517.001]
  • [Cites] Am J Hematol. 1993 Jan;42(1):7-12 [8416301.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1523-8 [8336190.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1328-33 [7882331.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2245-52 [9605773.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2912-8 [16675588.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6337-44 [17085643.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):16-21 [17210678.001]
  • [Cites] Radiat Res. 2009 Dec;172(6):666-76 [19929413.001]
  • [Cites] Biochem Pharmacol. 2000 Apr 15;59(8):983-91 [10692563.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2971-6 [11595684.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40647-51 [11517226.001]
  • [Cites] Prog Biophys Mol Biol. 2001 Nov;77(3):177-268 [11796141.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):402-14 [12538494.001]
  • (PMID = 20145183.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / L30 CA130084; United States / NCI NIH HHS / CA / U01 CA062502; United States / NCI NIH HHS / CA / UO1 CA62502; United States / NCI NIH HHS / CA / K12 CA076917; United States / NCI NIH HHS / CA / CA130084-01; United States / NCI NIH HHS / CA / L30 CA130084-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / L30 CA130084-01; United States / NCI NIH HHS / CA / K12 CA76917; United States / NCI NIH HHS / CA / P30 CA43703-17
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyridines; 0 / Thiosemicarbazones; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 9008-37-1 / Methemoglobin; EC 1.17.4.- / Ribonucleotide Reductases; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS165368; NLM/ PMC2822897
  •  go-up   go-down


3. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • Leiomyosarcoma accounted for 42.2% followed by carcinosarcoma (35.5%) and endometrial stromal sarcoma (18.6%).
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • Salvage surgery for isolated relapses was performed for 9/32 recurrent patients (28%) including 5 lung metastatectomies and 4 local pelvic resections.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. Jameel A, Jamil SN: Safety of cytotoxic chemotherapy during pregnancy. J Pak Med Assoc; 2007 Sep;57(9):449-52
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of cytotoxic chemotherapy during pregnancy.
  • OBJECTIVE: To To present an experience and results of treatment of pregnant cancer patients with cytotoxic chemotherapy from second trimester of pregnancy.
  • METHODS: Eighteen consecutive pregnant patients treated at Khyber Teaching Hospital, Peshawar between December 2000 and August 2006 for different types of malignancies are reported.
  • Six patients (33%) had breast cancer, four (22%) had chronic myeloid leukaemia, two (11%) had Hodgkin's disease, two (11%) had acute myeloid leukaemia and one each had recurrent ovarian carcinoma (5.7%), soft-tissue sarcoma (5.7%), acute lymphoblastic leukaemia (5.7%) and non-Hodgkin's lymphoma (5.7%).
  • RESULTS: Two patients were lost to follow-up after one course of chemotherapy while two patients chose to have therapeutic abortion.
  • Out of the remaining 14 patients, one patient had spontaneous abortion while one patient had an intra-uterine death of foetus during chemotherapy.
  • CONCLUSION: Chemotherapy during the second and third trimester of pregnancy can be safe if proper obstetric and radiologic monitoring is performed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytotoxins / adverse effects. Drug-Related Side Effects and Adverse Reactions. Pregnancy Complications. Pregnancy Outcome
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms / drug therapy. Pregnancy. Pregnancy Trimester, Second. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072640.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins
  •  go-up   go-down


5. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T: Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer; 2009 May 1;115(9):1867-74
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
  • BACKGROUND: : The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS).
  • METHODS: : Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS.
  • Quality-of-life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy.
  • Stable disease was noted in 3 of 12 patients (at 8 weeks, 12 weeks, and > or =77 weeks, respectively), and the median time to disease progression was 48 days.
  • No serious treatment-related adverse events occurred.
  • CONCLUSIONS: : Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%.
  • Although mifepristone was tolerated well, as a single agent, it provided limited response as a single agent in women with progesterone receptor-positive uterine tumors.
  • The authors concluded that further research into the best mode of application for mifepristone in the treatment of endometrial cancer is needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Endometrioid / drug therapy. Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Receptors, Progesterone / metabolism. Recurrence

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241422.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098258
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down


6. Kanjeekal S, Chambers A, Fung MF, Verma S: Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol; 2005 May;97(2):624-37
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.
  • OBJECTIVE: To conduct a systematic review of the literature regarding the systemic treatment of advanced uterine sarcoma and provide an evidence-based summary of the available literature.
  • "Uterine sarcoma," "leiomyosarcoma," "mixed mesodermal tumor," "chemotherapy," and "systemic therapy" were combined with the search terms for study designs.
  • In a randomized trial of doxorubicin versus doxorubicin plus cyclophosphamide for advanced or recurrent uterine sarcoma, doxorubicin produced an overall response rate (RR) of 19% and median survival of 11.6 months, which was similar to the response with combination chemotherapy (RR 19%, median survival 10.9 months).
  • A randomized trial comparing doxorubicin to doxorubicin with dacarbazine in women with advanced or recurrent uterine sarcoma demonstrated a significantly higher RR with the combination (P < 0.05), but no significant difference in survival.
  • CONCLUSIONS: Offering palliative chemotherapy to patients with advanced, unresectable uterine sarcoma who are symptomatic from this disease is a reasonable decision.
  • Doxorubicin is an option for women with advanced uterine sarcoma.
  • [MeSH-major] Mixed Tumor, Mesodermal / drug therapy. Sarcoma, Endometrial Stromal / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Female. Humans. Leiomyosarcoma / drug therapy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863170.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


7. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, Hirasawa T, Muramatsu T, Miyamoto T, Nasu S, Yasuda S, Kajiwara H, Yasuda M, Ide M: Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):854-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
  • We evaluated the usefulness of whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG-PET) for the detection of recurrence in follow-up patients after primary treatment of uterine sarcoma.
  • Eight patients with pathologically proven uterine sarcoma underwent FDG-PET, computed tomography (CT), and ultrasonography (US).
  • PET revealed recurrent sites in the intraperitoneum, liver, lung, bone, and retroperitoneal lymph nodes.
  • Positive PET findings did not affect the prognosis in three of the five recurrent patients; however, the remaining two patients consequently underwent the combination therapy consisting of surgery and chemotherapy and survived for more than 1 year after the positive FDG-PET results.
  • Application of PET imaging for the early detection of recurrent sites was useful for the decision of treatment strategy for patients with recurrent uterine sarcoma.
  • [MeSH-major] Carcinosarcoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed. Uterine Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681773.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Shamseddine A, Taher A, Abou-Mourad Y, Seoud M, Khalil A: Cure of metastatic uterine carcinosarcoma to lungs: a case report. Int J Gynecol Cancer; 2003 Jan-Feb;13(1):88-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cure of metastatic uterine carcinosarcoma to lungs: a case report.
  • Most patients with advanced or recurrent uterine sarcoma experience disease progression and ultimately die.
  • We present a case of uterine sarcoma with lung metastasis treated with systemic chemotherapy and with no evidence of disease for more than 5 years.
  • After four cycles of systemic chemotherapy with cisplatin and ifosfamide, the pulmonary nodules completely disappeared.
  • Currently she is still in complete remission after more than 5 years, but unfortunately she has developed myelodysplastic syndrome.
  • This is the first reported case in the literature of cured metastatic uterine carcinosarcoma to lungs, with long-term survival of 5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Ifosfamide / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12631227.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Fushiki H, Yoshimoto H, Ikoma T, Ota S: [A trial of biweekly paclitaxel administration in consideration of QOL for advanced or recurrent gynecologic cancer]. Gan To Kagaku Ryoho; 2005 May;32(5):691-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A trial of biweekly paclitaxel administration in consideration of QOL for advanced or recurrent gynecologic cancer].
  • At present there is no oral medicine available which is effective for advanced or recurrent case of elderly patients with gynecologic cancer.
  • We report that a low-dose biweekly paclitaxel administration preserves quality of life (QOL) and seems to be "tumor dormancy like" therapy of good compliance with few side effects.
  • A total of 11 cases were in ovarian cancer (5), uterine cancer (3), cervical cancer (2), and uterine sarcoma (1).
  • We performed a standard treatment as a first time treatment.
  • Afterwards, we obtained complete informed consent from the patients for progressive or recurrent cancer and administered biweekly paclitaxel 70 mg/m2 (80-100 mg/body) on an outpatient basis.
  • We reviewed the effect, side effect and compliance of the medication.
  • We judged the side effect based on the Japanese cancer treatment society common toxicity criteria.
  • An ovary cancer case patient lived for 67 months at best, an endometrial cancer case patient lived for 62 months at best, a cervical cancer case patient lived for 74 months at best, and a recurrent uterine sarcoma case patient lived for 76 months after recurrence and the QOL was good.
  • In these cases, we thought that a low-dose of biweekly paclitaxel administration was regarded as a therapy to preserve QOL without a serious side effect and a good compliance of medication.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Genital Neoplasms, Female / drug therapy. Paclitaxel / administration & dosage. Quality of Life
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / psychology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / psychology. Uterine Neoplasms / drug therapy. Uterine Neoplasms / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918575.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Lin JF, Slomovitz BM: Uterine sarcoma 2008. Curr Oncol Rep; 2008 Nov;10(6):512-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcoma 2008.
  • Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers.
  • The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma.
  • Most patients with uterine sarcomas are middle- to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma.
  • Surgery--including hysterectomy and resection of disease--serves as the main treatment modality.
  • Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature.
  • For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response.
  • For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Female. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / therapy. Medical Oncology / methods. Neoplasm Metastasis. Recurrence. Research Design. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Feb 15;112(4):820-30 [18189292.001]
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):513-7 [17935762.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):939-44 [9625851.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):270-94 [8001001.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):176-86 [12833470.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):43-8 [18445505.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):535-58 [8179071.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):370-4 [17009628.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1200-1 [18217961.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):8-13 [9454652.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):323-8 [18394689.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2170-82 [7127257.001]
  • [Cites] Arch Gynecol Obstet. 2002 Apr;266(2):92-5 [12049303.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Obstet Gynecol. 1994 Jun;83(6):1015-20 [8190416.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):739-48 [11172957.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(6):541-6 [10215437.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):821-7 [9311600.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2239-47 [3179938.001]
  • [Cites] Adv Anat Pathol. 2000 Sep;7(5):257-81 [10976906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):47-52 [10219793.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):223-7 [2307449.001]
  • [Cites] Obstet Gynecol. 1994 Mar;83(3):414-8 [8127535.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1972-9 [9806656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2127-30 [3793549.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):370-5 [7705670.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1009-15 [8281375.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):630-4 [17320937.001]
  • [Cites] Hum Pathol. 1970 Sep;1(3):331-49 [4330001.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):369-73 [7997731.001]
  • [Cites] Cancer. 1978 Sep;42(3):1161-70 [698911.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):247-53 [8910635.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):313-5 [18534248.001]
  • (PMID = 18928666.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


11. Bai P, Zhang W, Sun J: [Combination chemotherapy of uterine sarcomas]. Zhonghua Zhong Liu Za Zhi; 2000 Jan;22(1):80-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy of uterine sarcomas].
  • OBJECTIVE: To study the results of combination chemotherapy of uterine sarcoma after operation and recurrent tumor.
  • METHODS: One hundred seventy-four cases of three major pathological subtypes of uterine sarcomas were treated in the Cancer Hospital from 1960 to 1996.
  • Clinical data were analyzed of 51 cases of uterine sarcomas treated with postoperative adjuvant chemotherapy and 38 cases with recurrent tumors received 98 courses of chemotherapy.
  • They were divided into 4 groups according to the adjuvant chemotherapy regimen: single drug, VAC, VAD, and other regimens.
  • Chemotherapy regimens for recurrent tumors were VAD, PA/PAC, and other combination regimens including etoposide, ifosfamide, cisplatin, adriamycin.
  • RESULTS: The 5-year survival rate of stage I-II uterine sarcoma patients was 54.9% receiving adjuvant chemotherapy.
  • The survival rate was related to the number of chemotherapy course.
  • The chemo-sensitivity of various pathological types of recurrent uterine sarcomas was not different.
  • CONCLUSION: The 5-year survival rate does not improve in patients with stage I-II uterine sarcomas given postoperative chemotherapy.
  • The results of new treatment regimens such as EPA, IA, etc., must await further clinical observation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Therapy, Combination. Female. Humans. Mitolactol / administration & dosage. Mitomycins / administration & dosage. Postoperative Period. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11776610.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mitomycins; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; LJ2P1SIK8Y / Mitolactol; ADM protocol; VAD combination
  •  go-up   go-down


12. Piura B, Rabinovich A: Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. Eur J Gynaecol Oncol; 2005;26(3):275-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
  • PURPOSE OF INVESTIGATION: To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas.
  • METHODS: The hospital records of five patients with advanced/recurrent uterine sarcomas who had combination chemotherapy with doxorubicin and ifosfamide-mesna were retrospectively reviewed.
  • Dose intensity, relative dose intensity and average relative dose intensity (ARDI) of chemotherapy were calculated.
  • CONCLUSION: Although the combination of doxorubicin and ifosfamide has certain activity in advanced/recurrent uterine sarcomas, the toxicity is of much concern and the results of treatment in terms of response duration and survival are poor.
  • [MeSH-major] Ifosfamide / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Doxorubicin / administration & dosage. Female. Humans. Mesna / therapeutic use. Middle Aged. Neoplasm Staging. Protective Agents / therapeutic use. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991525.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protective Agents; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Viereck V, Huschmand Nia A, Pauer HU, Emons G, Krauss T: [Diagnosis and therapy of uterine sarcoma]. Zentralbl Gynakol; 2002 Nov;124(11):506-10
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of uterine sarcoma].
  • [Transliterated title] Diagnostik und Therapie der Uterussarkome.
  • Radical surgery in stage I and II uterine sarcoma removing all tumor manifestations is the only curative therapy option for early stage disease.
  • For these tumors adjuvant radiation and/or adjuvant chemotherapy may be recommended after surgical therapy.
  • Adjuvant therapy however, should preferably be considered for uterine stromal sarcomas and mixed mesodermal tumors.
  • The toxicity of radiation and/or chemotherapy is greater than any possible benefit for patients with leiomysarcomas as these tumors rarely respond to radiation or chemotherapy.
  • For advanced (> stage I and II) and recurrent disease, curative therapy options are not available and palliative therapy for these patients has to take into consideration the negative side effects and weigh up quality of life against an often very limited possible benefit of such therapy.
  • [MeSH-major] Sarcoma / diagnosis. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796843.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


14. Gibbon D, Wagreich A, Nieves-Neira W, Shih W, Ziang W, Rodriguez-Rodriguez L, Germino J: A retrospective review of metastatic or recurrent uterine sarcomas treated with paclitaxel, carboplatin, and gemcitabine chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of metastatic or recurrent uterine sarcomas treated with paclitaxel, carboplatin, and gemcitabine chemotherapy.
  • : 5143 Background: The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4-26 months.
  • The primary objective of this study was to assess the activity of paclitaxel, carboplatin and gemcitabine (GCP) in the treatment of primary, metastatic, or recurrent uterine sarcomas.
  • The efficacy of the GCP regimen in women with metastatic or recurrent uterine sarcomas was assessed.
  • Patients were treated on a phase II soft tissue sarcoma protocol or off protocol by the gynecologic oncology division.
  • 4 patients were inevaluable; 3 patients for less than one month of therapy and 1 patient without measurable disease.
  • Histology included 6 leiomyosarcomas (LMS), 1 endometrial stromal sarcoma (ESS), and 2 carcinosarcomas (CS).
  • Median time to progression for all patients was 10 months (95% CI {83 -530 days}).
  • CONCLUSIONS: GCP combination chemotherapy demonstrates moderate activity, with acceptable toxicity, in patients with advanced uterine sarcomas.
  • Given the durable median time to progression and overall survival, this pilot data supports the evaluation of this regimen in a multi-institutional phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016800.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Murakami M, Tsukada H, Ikeda M, Watanabe M, Muramatsu T, Miyamoto T, Makino T, Yasuda S, Ide M, Nasu S: Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma.
  • : 5100 Background: Uterine sarcomas are relatively rare and its prognosis is poor.
  • Accurate diagnosis of the metastatic sites is important for the treatment strategy.
  • Unfortunately current diagnostic techniques, including CT, MRI, and ultrasonography (US) are not efficient for the detection of recurrence.
  • There is little report of the experience with whole-body 18 fluorodeoxyglucose (FDG)-PET for the detection of recurrence in the follow up of patients with uterine sarcomas.
  • The purpose of this study is to evaluate the availability of FDG-PET for the detection of recurrence in patients with uterine sarcomas.
  • METHODS: Twelve patients with pathologically proven uterine sarcomas (nine leiomyosarcoma and three carcinosarcoma) took FDG-PET, CT, MRI and US for the purpose of the detection of recurrence after the primary treatment.
  • PET scan showed all recurrent sites of intraperitoneum, liver, lung and retroperitoneal lymph nodes.
  • Positive results of PET scan did not affect the prognosis in four patients, but another patient with solitary intraperitoneal tumor by PET scan could received the chemotherapy and operation, which histologically confirmed the recurrence of leiomyosarcoma.
  • Application of PET scan for the early detection of recurrence may affect the prognosis of some patients with uterine sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Odunsi K, Moneke V, Tammela J, Ghamande S, Seago P, Driscoll D, Marchetti D, Baker T, Lele S: Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer; 2004 Jul-Aug;14(4):659-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up.
  • Data on adjuvant chemotherapy in early-stage uterine sarcomas are conflicting and most often based on small patient groups with relatively short duration of follow-up.
  • This study examines the efficacy and results of long-term follow-up of a multiagent chemotherapy regimen of cyclophosphamide, vincristine, doxorubicin, and dacarbazine (CYVADIC) as adjuvant treatment for patients with stage I uterine sarcoma.
  • Between 1982 and 1999, 24 evaluable patients with completely staged uterine sarcomas received adjuvant multiagent chemotherapy with vincristine sulfate (1mg /m(2)) on days 1 and 4, doxorubicin (40 mg /m(2)) and cyclophosphamide (400 mg /m(2)) on day 2, and dacarbazine (200 mg /m(2)) on days 1 through 4 for a total of nine monthly cycles or until recurrence of disease was documented.
  • The patients received 206 of a planned 216 cycles of chemotherapy.
  • Eight patients (33%) developed recurrent disease.
  • The median time to recurrence was 19 months (range 7-184 months).
  • Adjuvant CYVADIC chemotherapy appears to be safe and well tolerated in patients with stage I uterine sarcomas.
  • Our data provide information on the longest duration of follow-up ever reported and suggests that CYVADIC may have a potential role in the adjuvant treatment of early-stage uterine sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15304162.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CYVADIC protocol
  •  go-up   go-down


17. Gadducci A, Cosio S, Romanini A, Genazzani AR: The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol; 2008 Feb;65(2):129-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of patients with uterine sarcoma: a debated clinical challenge.
  • Uterine sarcomas include a heterogeneous group of rare tumours that usually have an aggressive clinical behaviour and a poor prognosis.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the standard surgical treatment.
  • Pelvic and/or para-aortic lymphadenectomy is indicated for carcinosarcoma, but not for leiomyosarcoma and undifferentiated endometrial sarcoma.
  • Some recent data on low numbers of patients with low-grade endometrial stromal sarcoma appear to show an incidence of nodal involvement higher than previously expected, thus suggesting a role for lymphadenectomy in this malignancy.
  • Postoperative treatment of uterine sarcomas has been long debated.
  • There is little evidence in the literature supporting the use of adjuvant chemotherapy in any gynaecological sarcomas except for carcinosarcomas.
  • However, uterine sarcomas have a high tendency to develop distant recurrences, and recent data on adjuvant chemotherapy in soft tissue sarcomas are promising.
  • As for the drugs to be used, it is worth noting that in a Swiss study, the combination of ifosfamide (IFO) and doxorubicin (DOX) obtained similar response rates in advanced gynaecological sarcomas and in advanced soft tissue sarcomas of other sites.
  • In our decision-making scheme for early-stage disease, patients with leiomyosarcoma or undifferentiated endometrial sarcoma should receive adjuvant doxorubicin/epidoxorubicin (EPIDX)+ifosfamide, and those with carcinosarcoma should be treated with adjuvant cisplatin (CDDP)-based chemotherapy.
  • The same drug regimens are used for the treatment of advanced disease.
  • Sequential pelvic radiotherapy following chemotherapy could be delivered to selected cases.
  • Recurrent disease often requires the integration of different therapeutic modalities, but no curative option is currently available with the possible exception of surgery for lung metastases and hormone therapy with or without debulking surgery for recurrent low-grade endometrial stromal sarcoma.
  • Patients should be encouraged to enter clinical trials designed to identify new active drugs for these malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706430.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 177
  •  go-up   go-down


18. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I: Clinical management of uterine sarcomas. Lancet Oncol; 2009 Dec;10(12):1188-98
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical management of uterine sarcomas.
  • Malignant pure mesenchymal uterine tumours encompass endometrial stromal sarcoma (ESS), uterine leiomyosarcoma, and undifferentiated sarcomas.
  • This Review discusses pathology, preoperative diagnosis, and standard treatment of uterine leiomyosarcoma and low-grade ESS (distinct from undifferentiated uterine sarcomas), with an emphasis on targeted treatment.
  • We show that several features on ultrasonography and MRI can raise suspicion of a uterine sarcoma; however, there are no pathognomonic features on any imaging technique.
  • For both ESS and uterine leiomyosarcoma, hysterectomy with bilateral salpingo-oophorectomy, but without lymphadenectomy, is the standard surgical treatment for early stage disease.
  • The clinical benefit of chemotherapy is limited, which underscores the importance of targeted therapy.
  • ESS and uterine leiomyosarcoma are driven by different pathways, resulting in a different clinical behaviour.
  • Uterine leiomyosarcoma is notorious for its aggressive growth and poor outcome.
  • Individualisation of treatment is mandatory, because randomised trials are almost non-existent.
  • The progesterone and oestrogen receptors are clinically important targets for most primarily advanced or recurrent ESS and a subset of recurrent uterine leiomyosarcomas.
  • Potential future targets and targeted treatments that are under investigation are presented for both entities.
  • [MeSH-major] Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959075.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 90
  •  go-up   go-down


19. Hensley ML: Uterine/female genital sarcomas. Curr Treat Options Oncol; 2000 Jun;1(2):161-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine/female genital sarcomas.
  • Choosing the best management of uterine and vulvo-vaginal sarcomas depends on careful histologic review of the pathologic specimen.
  • Prognosis and treatment vary greatly depending on specific histology, grade, and tumor stage.
  • Adjuvant radiation decreases local recurrence rates for uterine sarcomas, but has not been clearly shown to improve overall survival.
  • It is frequently used as adjuvant therapy for resected high-grade or margin-positive vulvo-vaginal sarcomas, and for endometrial stromal sarcomas.
  • Adjuvant chemotherapy has not been demonstrated to improve survival in vulvo-vaginal sarcomas, with the exception of vulvo-vaginal rhabdomyosarcomas, nor has it been demonstrated to improve survival in uterine sarcomas.
  • Chemotherapy may be used for recurrent or persistent disease.
  • The choice of agent depends on the histologic type of sarcoma.
  • [MeSH-major] Sarcoma / therapy. Uterine Neoplasms / therapy. Vaginal Neoplasms / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):105-9 [8349151.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Obstet Gynecol. 1979 Jul 1;134(5):557-64 [453295.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Obstet Gynecol. 1985 May;65(5):699-704 [2984620.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):311-6 [6197155.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2487-92 [2684386.001]
  • [Cites] Am J Obstet Gynecol. 1992 Feb;166(2):556-9 [1536229.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Obstet Gynecol. 1989 Jan;73(1):75-8 [2462203.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2003-7 [3756818.001]
  • [Cites] Obstet Gynecol. 1984 Apr;63(4):550-6 [6322081.001]
  • [Cites] Am J Obstet Gynecol. 1990 Apr;162(4):968-74; discussion 974-6 [2327466.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1264-7 [3815302.001]
  • [Cites] Am J Obstet Gynecol. 1987 Mar;156(3):660-2 [3826216.001]
  • [Cites] Radiother Oncol. 1990 Feb;17(2):123-32 [2157241.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1847-53 [2230871.001]
  • [Cites] Obstet Gynecol. 1984 Aug;64(2):173-8 [6738952.001]
  • [Cites] Gynecol Oncol. 1985 Mar;20(3):281-9 [3838290.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3333-55 [10506637.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):223-7 [2307449.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):389-95 [10366465.001]
  • [Cites] Obstet Gynecol. 1973 Oct;42(4):522-6 [4742656.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):399-402 [3456457.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):202-5 [1592288.001]
  • [Cites] Obstet Gynecol. 1986 Nov;68(5):709-14 [3763088.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1736-44 [10561210.001]
  • [Cites] Obstet Gynecol. 1985 Aug;66(2):262-6 [3839576.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50 [2453004.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Obstet Gynecol. 1979 Feb;53(2):213-7 [418977.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):233-40 [3280809.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):232-7 [10021306.001]
  • (PMID = 12057054.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


20. Li X, Liu L, Wu L: [Ifosfamide combination chemotherapy for advanced gynecologic malignancies]. Zhonghua Zhong Liu Za Zhi; 2000 Jul;22(4):330-2
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ifosfamide combination chemotherapy for advanced gynecologic malignancies].
  • OBJECTIVE: To evaluate the clinical efficacy and toxicity of ifosfamide (IFO) combination chemotherapy in patients with advanced gynecologic malignancies.
  • Of the 34 patients, 26 with epithelial cancer of the ovary were previously treated with cisplatin-containing combination chemotherapy but failed to respond or recurred after treatment.
  • The remaining 8 patients with uterine sarcoma (5 cases), squamous-cell carcinoma of the uterine cervix with metastases to the liver or bone (2 cases), and endometrial carcinoma with lung metastases (1 case) were treated with IFO combination chemotherapy.
  • At least two courses of treatment were given unless tumor progression occurred after the first course.
  • Two patients with cervical carcinoma and two of five patients with uterine sarcoma responded to IFO combination chemotherapy.
  • CONCLUSION: IFO combination chemotherapy is effective in treating recurrent or progressive gynecologic malignancies, especially PDD-sensitive ones.
  • Myelosuppression is relatively severe which may be due to prior long term and intensive chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ifosfamide / administration & dosage. Ovarian Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11778564.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Weber WA, Wieder H: Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging; 2006 Jul;33 Suppl 1:27-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring chemotherapy and radiotherapy of solid tumors.
  • The clinical value of FDG-PET for differentiation of residual or recurrent viable tumor and therapy-induced fibrosis or scar tissue has been documented for various solid tumors.
  • Furthermore, there are now several reports suggesting that quantitative assessment of therapy-induced changes in tumor FDG uptake may allow prediction of tumor response and patient outcome very early in the course of therapy.
  • In nonresponding patients, treatment may be adjusted according to the individual chemo- and radiosensitivity of the tumor tissue.
  • Since the number of alternative treatments for solid tumors (e.g., second-line chemotherapy agents, protein kinase, or angiogenesis inhibitors) is continuously increasing, early prediction of tumor response to chemotherapy and radiotherapy by FDG-PET has enormous potential to "personalize" treatment and to reduce the side-effects and costs of ineffective therapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Esophageal Neoplasms / diagnostic imaging. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Female. Head and Neck Neoplasms / diagnostic imaging. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Humans. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Monitoring, Physiologic / methods. Radionuclide Imaging. Radiopharmaceuticals. Sarcoma / diagnostic imaging. Sarcoma / drug therapy. Sarcoma / radiotherapy. Uterine Cervical Neoplasms / diagnostic imaging. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1167-75 [15909196.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7445-53 [16157939.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1842-50 [7965167.001]
  • [Cites] J Nucl Med. 1993 May;34(5):773-9 [8478710.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):159-171 [14516540.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Thorac Surg. 2004 Jan;77(1):254-9; discussion 259 [14726072.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Head Neck. 2002 Feb;24(2):127-35 [11891942.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5928-34 [16115935.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):339-48 [15578712.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2167-71 [15169804.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23 (33):8362-70 [16293866.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Cancer. 2002 Jun 15;94(12 ):3277-84 [12115361.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]
  • [Cites] J Clin Oncol. 1996 Mar;14 (3):700-8 [8622014.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] J Nucl Med. 2005 Sep;46(9):1481-7 [16157531.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1470-7 [7751894.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2797-803 [11387350.001]
  • [Cites] Radiology. 1995 Jul;196 (1):167-73 [7784562.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 [6577010.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1352-61 [1696309.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):892-9 [15573074.001]
  • [Cites] Radiology. 2003 Mar;226(3):906-10 [12616024.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Arch Neurol. 1989 Dec;46(12 ):1302-7 [2556096.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1806-14 [14602864.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Thorac Surg. 2002 Jan;73(1):259-64; discussion 264-6 [11834020.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):811-9 [14762698.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:4S-14S [14736831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):412-8 [15380574.001]
  • [Cites] Ann Thorac Surg. 2004 Dec;78(6):1903-9; discussion 1909 [15560998.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1285-92 [12663716.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1776-85 [15386332.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):283-5 [11208816.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14 ):2651-7 [12860940.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5661-2 [16115898.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):97-106 [16397030.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1838-42 [15534052.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):530-41 [15297944.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10 ):1637-43 [10520703.001]
  • [Cites] J Nucl Med. 1999 Jul;40(7):1085-90 [10405124.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5117-25 [15955906.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Oral Oncol. 2003 Feb;39(2):170-7 [12509971.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):300-9 [11224616.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):900-8 [14990646.001]
  • [Cites] Lung Cancer. 2002 Feb;35(2):179-87 [11804691.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):361-8 [11996465.001]
  • [Cites] Chest. 2001 Nov;120(5):1584-91 [11713138.001]
  • (PMID = 16688451.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 66
  •  go-up   go-down


22. Kortmann B, Reimer T, Gerber B, Klautke G, Fietkau R: Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. Strahlenther Onkol; 2006 Jun;182(6):318-24
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus.
  • BACKGROUND: Uterine sarcomas are rare tumors.
  • Until now, no data on the treatment of recurrent or advanced uterine sarcomas using concurrent radiochemotherapy (RCT) has been available.
  • PATIENTS AND METHODS: From 01/1997 to 03/2004, seven patients with locally recurrent (n = 6) or locally advanced uterine sarcomas (n = 1) received concurrent RCT after tumor surgery (R1/2 resection in 3/7 patients).
  • A total radiation dose of 45 Gy was applied in single doses of 1.8 Gy using an external-beam technique; in addition, three to four intracavitary doses of 5 Gy were applied.
  • Concurrent chemotherapy was generally administered as follows: 1.2 g/m(2) ifosfamide on days 1-5 and 29-33 in combination with 50 or 40 mg/m(2) adriamycin on days 2 and 30.
  • 3/7 patients received further cycles of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Conformal / methods. Sarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703286.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH: Total pelvic exenteration for primary and recurrent malignancies. World J Surg; 2009 Jul;33(7):1502-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pelvic exenteration for primary and recurrent malignancies.
  • In locally advanced and recurrent pelvic malignancies, radical margins are sometimes difficult to obtain because of close relation to or growth in adjacent organs/structures.
  • METHODS: Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma.
  • Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging.
  • Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively.
  • Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%.
  • CONCLUSIONS: Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.
  • [MeSH-minor] Adult. Aged. Brachytherapy / methods. Cohort Studies. Disease-Free Survival. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Female. Hospital Mortality / trends. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Postoperative Complications / mortality. Probability. Prognosis. Proportional Hazards Models. Quality of Life. Radiotherapy, Adjuvant. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Retrospective Studies. Risk Assessment. Survival Analysis. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Nov;29(9):743-6 [14602493.001]
  • [Cites] Dig Surg. 2003;20(3):192-9; discussion 200 [12759498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):106-12 [14697427.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):680-3 [14766266.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):972-5 [15498643.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6 [8154965.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Urol. 1999 Apr;161(4):1057-66 [10081838.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):99-102 [10502433.001]
  • [Cites] Surg Clin North Am. 1950 Oct;30(5):1511-21 [14782163.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2047-53; discussion 2053-4 [15657653.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):524-8 [15863155.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):918-28 [15785886.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1257-65 [16912909.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):452-8 [17071043.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):243-8 [16950559.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1438-48 [10566532.001]
  • [Cites] J Am Coll Surg. 2000 Jan;190(1):78-83 [10625236.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1546-9 [11775189.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • (PMID = 19421811.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2691931
  •  go-up   go-down


24. Ashraf-Ganjoei T, Behtash N, Shariat M, Mosavi A: Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol; 2006;4:50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases.
  • BACKGROUND: Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the USA or Europe per year.
  • The aim of this study was to evaluate the behavior of low-grade endometrial stromal sarcoma (LGESS) in relation to their clinical and pathological features and to identify possible prognostic factors.
  • Endometrial stromal sarcoma is characterized by proliferations composed of cells with Endometrial stromal cell differentiation.
  • Low-grade endometrial stromal sarcoma has an infiltrating margin and typically show extensive worm-like vessel invasion.
  • Radiotherapy as adjuvant therapy was administered to four patients (28.5%).
  • The median follow-up time was 45.6 months (range 24-84).
  • The recurrent diseases were treated with surgery, chemotherapy, and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):318-21 [15963554.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):632-6 [15581975.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):412-3; author reply 413 [15491769.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):256-9 [15385142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1366-73 [14630275.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):37-43 [12821339.001]
  • [Cites] Med Oncol. 2003;20(1):87-93 [12665689.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):256-60 [12040283.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] J Clin Pathol. 1999 Mar;52(3):198-202 [10450179.001]
  • [Cites] Am J Obstet Gynecol. 2000 May;182(5):1140-1 [10819848.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):120-3 [11006043.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):160-5 [11330943.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):243-5 [16054205.001]
  • (PMID = 16895611.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1560376
  •  go-up   go-down


25. Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, Cass I: Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol; 2009 Dec;115(3):466-71
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
  • OBJECTIVES.: The utility of hormone therapy in the management of uterine sarcomas is poorly defined.
  • We hypothesize that estrogen receptor (ER) expression is common in uterine sarcomas, and carries prognostic significance.
  • Further, we hypothesize that ER-positive uterine sarcomas respond to hormone therapy.
  • METHODS.: We retrospectively reviewed charts of patients with uterine sarcomas.
  • Four patients received hormonal treatment in the adjuvant setting and remained in remission (range of follow up: 18-68 months).
  • Eighteen patients received hormone therapy in the setting of recurrent or progressive disease: fourteen (78%) demonstrated stable disease or complete or partial response (range of follow up: 6-124 months).
  • CONCLUSIONS.: ER expression is common and is associated with improved overall survival in uterine sarcomas.
  • Hormone therapy should be considered in patients with primary and recurrent ER-positive uterine sarcomas.
  • [MeSH-major] Receptors, Estrogen / biosynthesis. Sarcoma / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adenosarcoma / drug therapy. Adenosarcoma / metabolism. Adenosarcoma / pathology. Antineoplastic Agents, Hormonal / pharmacology. Aromatase Inhibitors / pharmacology. Carcinosarcoma / drug therapy. Carcinosarcoma / metabolism. Carcinosarcoma / pathology. Female. Humans. Retrospective Studies. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / metabolism. Sarcoma, Endometrial Stromal / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767065.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Receptors, Estrogen
  •  go-up   go-down


26. Burke C, Hickey K: Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol; 2004 Nov;104(5 Pt 2):1182-4
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue.
  • BACKGROUND: Endometrial stromal sarcoma can present management difficulties due to its lack of response to conventional chemotherapy and radiotherapy.
  • Various hormonal therapies have been shown to reduce tumor volume in both primary and recurrent disease.
  • CASE: A woman who underwent myomectomy was discovered to have a low-grade endometrial stromal sarcoma.
  • Treatment with the gonadotropin-releasing hormone (GnRH) analogue triptorelin before surgery had produced reduction in uterine size.
  • The woman developed tumor recurrence six months after definitive surgical treatment.
  • Biopsy results confirmed recurrent low-grade endometrial stromal sarcoma with moderate estrogen and progesterone receptor positivity.
  • CONCLUSION: Control of progression of a recurrent endometrial stromal sarcoma was achieved with the GnRH analogue triptorelin.
  • This is the first report in the English-language literature during a 30-year period of single-agent GnRH analogue being an effective treatment intervention in this context.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / pathology. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Intraoperative Care / methods. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516445.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


27. Yokoyama Y, Ono Y, Sakamoto T, Fukuda I, Mizunuma H: Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection. Gynecol Oncol; 2004 Mar;92(3):999-1001
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection.
  • BACKGROUND: The endometrial stromal sarcoma (ESS) is a rare neoplasm of the uterine origin.
  • The chemotherapy was effective against the recurrent tumors except for intracardiac site.
  • Pathological examination confirmed intracardiac recurrent low-grade ESS.
  • [MeSH-major] Endometrial Neoplasms / pathology. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Sarcoma, Endometrial Stromal / secondary. Sarcoma, Endometrial Stromal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984976.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Amr SS, Sheikh SM: Polypoid endocervical stromal sarcoma with heterologous elements. Report of a case with review of the literature. Eur J Obstet Gynecol Reprod Biol; 2000 Jan;88(1):103-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid endocervical stromal sarcoma with heterologous elements. Report of a case with review of the literature.
  • A 44 year old woman presented with six recurrent endocervical polyps within the span of 28 months.
  • No chemotherapy or radiotherapy was administered.
  • The patient is alive and free of recurrent disease 9 years following surgery.
  • [MeSH-major] Polyps / surgery. Sarcoma / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Hysterectomy. Stromal Cells / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10659927.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] IRELAND
  • [Number-of-references] 12
  •  go-up   go-down


29. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ: Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol; 2010 May;117(2):248-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
  • PURPOSE: This multi-institutional phase II trial assessed the activity and toxicity of imatinib mesylate and explored c-Kit and platelet-derived growth factor receptor (PDGFR)-beta in recurrent or persistent uterine carcinosarcoma.
  • METHODS: Women with measurable uterine carcinosarcoma, who had a performance status of 0, 1, or 2 and had received up to two prior treatment regimens, were eligible and treated with a 600-mg daily oral dose of imatinib mesylate until disease progression or unacceptable toxicity.
  • One subject had a PFS time >or=6 months, yielding the only patient with stable disease.
  • Positive expression of c-Kit or PDGFR-beta was observed in 88% (14/16) or 40% (6/15) and in 56% (9/16) or 73% (11/15) of cases in the sarcoma and carcinoma component of the tumor, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Middle Aged. Proto-Oncogene Proteins c-akt / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20189232.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.11.1 / AKT2 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


30. Garrett A, Quinn MA: Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol; 2008 Apr;22(2):407-21
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapies and gynaecological cancers.
  • Hormonal therapy has an established place in the management of women with gynaecological malignancies, including first-line therapy for recurrent receptor-positive endometrial cancer and low-grade stromal sarcoma.
  • There is no place for adjuvant hormonal treatment of these cancers after primary surgery.
  • Primary treatment with either oral or intra-uterine progestagens to preserve fertility in younger women with endometrial carcinoma is effective in about 70% of cases.
  • Response rates to tamoxifen in advanced/recurrent ovarian cancers approximates 10%.
  • To the authors' knowledge, no studies that reasonably compare different progestagens, different routes of therapy, different doses and different hormonal preparations have been published.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Estrogen Replacement Therapy. Female. Humans. Ovarian Neoplasms / drug therapy. Progestins / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Tamoxifen / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884734.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Progestins; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 55
  •  go-up   go-down


31. Krasner C: Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol; 2007 Aug-Sep;106(1-5):76-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The favorable toxicity profile of aromatase inhibitors led to trials of these agents for the treatment of relapsed epithelial ovarian cancer.
  • Endometrial cancers, particularly type I lesions, are often treated with hormonal manipulation, most commonly with progestins, but also with antiestrogens such as tamoxifen.
  • A trial of aromatase inhibition in the treatment of recurrent endometrial cancer showed minimal responses.
  • Endometrial stromal sarcoma, an uncommon uterine malignancy, has shown response to hormonal treatments, with multiple case reports of efficacy of aromatase inhibition.
  • Despite the rarity of some of these tumor types, rare tumor study groups, such as within the Gynecologic Oncology Group, should make an effort to prospectively define the utility of these treatments.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Female / enzymology. Sarcoma / drug therapy
  • [MeSH-minor] Animals. Female. Hormones / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826626.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Hormones
  • [Number-of-references] 29
  •  go-up   go-down


32. Ruiz Tovar J, Reguero Callejas ME, Arano Bermejo JI, Capote Armas LF, González-Palacios Martínez F, Cabañas Navarro L: Malignant mixed Mullerian tumors. Clin Transl Oncol; 2006 Feb;8(2):129-32
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinic pathological features of 3 uterine MMMTs are reported here.
  • Treatment in 2 patients was hysterectomy with double ooforectomy, and resection of the pelvic mass was the treatment in the third case.
  • Adjuvant radio chemotherapy was administrated in 2 of the 3 cases.
  • Follow-up revealed recurrent pelvic tumour in 1 patient at 59 months, and breast metastases at 20 months in the second one.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / secondary. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Fatal Outcome. Female. Femoral Neoplasms / secondary. Humans. Hysterectomy. Ifosfamide / administration & dosage. Ilium. Middle Aged. Neoplasms, Second Primary. Ovariectomy. Paclitaxel / administration & dosage. Palliative Care. Pelvic Neoplasms / secondary. Pelvic Neoplasms / surgery. Prognosis. Radiotherapy, Adjuvant. Sarcoma, Ewing. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurgie. 1996;121(3):198-202 [8945826.001]
  • [Cites] J Obstet Gynaecol. 2003 May;23(3):301-3 [12850867.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Jun;90(6):562-9 [6305395.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):717-24 [8616764.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • (PMID = 16632428.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


33. Emoto M, Naganuma Y, Choijamts B, Ohno T, Yoshihisa H, Kanomata N, Kawarabayashi T, Aizawa M: Novel chemoembolization using calcium-phosphate ceramic microsphere incorporating TNP-470, an anti-angiogenic agent. Cancer Sci; 2010 Apr;101(4):984-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to develop a new method of chemoembolization to improve the therapeutic effectiveness and safety profile of cancer treatment.
  • The human uterine sarcoma cell line FU-MMT-3 was used in this study because this tumor is aggressive and also exhibits a poor response to radiotherapy or any chemotherapy currently used.
  • The calcium-phosphate ceramic microspheres loaded with TNP-470, an anti-angiogenic agent, were injected into FU-MMT-3 xenografts in nude mice three times per week for 8 weeks.
  • The treatment using TNP-470-loaded microspheres suppressed tumor growth, compared to treatment with TNP-470 alone, microspheres alone, and the control.
  • The mean tumor weight after treatment using TNP-470-loaded microspheres was significantly lower than that after treatment with microspheres alone.
  • These ceramic microspheres were remarkably embolized in tumor microvessels as well as in the feeding arteries and a significant reduction of intratumoral vascularity was also demonstrated following treatment with TNP-470-loaded microspheres.
  • Severe loss of body weight was not observed in any mice treated with the TNP-470-loaded microspheres, compared to treatment with TNP-470 alone.
  • These results suggest that targeting tumor vasculature in human uterine sarcoma using calcium-phosphate microspheres might be more effective and safer than the treatment that employs anti-angiogenic agent alone.
  • This new chemoembolization method incorporating an anti-angiogenic agent may contribute to the effective treatment of locally advanced or recurrent solid tumors.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Uterine Neoplasms

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20109162.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Calcium Phosphates; 0 / Cyclohexanes; 0 / Sesquiterpenes; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


34. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol; 2000 Nov;79(2):147-53
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival.
  • METHODS: Patients were randomized to receive ifosfamide (1.5 g/m(2)/day) times 5 days every 3 weeks for eight courses with mesna uroprotection, with or without cisplatin (20 mg/m(2)/day) times 5 days.
  • No patient had received previous chemotherapy.
  • Percentages of adverse effects reported in 191 patients receiving chemotherapy included (ifosfamide/cisplatin-ifosfamide) grade 3 or 4 granulocytopenia (36/60), grade 3 or 4 anemia (8/17), grade 3 or 4 central nervous system toxicity (19/14), and grade 3 or 4 peripheral neuropathy (1/12).
  • Treatment may have contributed to the deaths of 6 patients treated with full doses of ifosfamide and cisplatin for 5 days.
  • The proportion of patients responding to ifosfamide alone versus ifosfamide-cisplatin therapy was (0.36 versus 0.54) overall, 0.47 versus 0.61 for pelvic, 0.21 versus 0.54 for lung, and 0.33 versus 0.40 for "other" metastatic sites of measurable disease.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Ifosfamide / therapeutic use. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • [CommentIn] Gynecol Oncol. 2000 Nov;79(2):145-6 [11063635.001]
  • (PMID = 11063636.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


35. Karseladze AI, Filipova NA, Navarro S, Llombart-Bosch A: Primitive neuroectodermal tumor of the uterus. A case report. J Reprod Med; 2001 Sep;46(9):845-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The curettage specimen was interpreted as poorly differentiated sarcoma.
  • The cells were positive for neurogenic marker protein gene product, neuron-specific enolase and Ewing's sarcoma-related HBA-71.
  • The patient received combined therapy, external radiation to the pelvis and chemotherapy.
  • Four years later she was alive, without signs of recurrent tumor.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antibodies, Neoplasm / isolation & purification. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hysterectomy. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584489.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


36. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C: A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs; 2007 Aug;25(4):335-41
Hazardous Substances Data Bank. Ixabepilone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with advanced, recurrent solid tumors who had received <or=2 prior cytotoxic regimens for recurrent disease were treated with gemcitabine over 90 min on days 1 and 8 plus BMS-247550 over 3 h on day 8, every 21 days in a phase I study.
  • Dose-limiting toxicity definitions were based on severe myelosuppression, or grade 3 or 4 treatment-related non-hematologic toxicity, or dose delay of greater than 2 weeks due to treatment toxicity observed in the first treatment cycle.
  • Treatment-related toxicities included neutropenia, thrombocytopenia, neutropenic fever, hypophosphatemia, and hyponatremia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoma, Small Cell / drug therapy. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Epothilones / administration & dosage. Female. Humans. Kidney Neoplasms / drug therapy. Leukopenia / chemically induced. Lung Neoplasms / drug therapy. Male. Melanoma / drug therapy. Middle Aged. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Urinary Bladder Neoplasms / drug therapy. Uterine Neoplasms / drug therapy. Water-Electrolyte Imbalance / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8724-9 [16314632.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1439-46 [15735119.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):169-70 [12701971.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1082-8 [17261851.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):314-9 [14751176.001]
  • [Cites] J Antibiot (Tokyo). 1996 Jun;49(6):560-3 [8698639.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15 [8893876.001]
  • [Cites] Anticancer Drugs. 2004 Jul;15(6):553-8 [15205596.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):593-6 [13678730.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):515-20 [16699973.001]
  • (PMID = 17364235.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA69856
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; K27005NP0A / ixabepilone
  •  go-up   go-down






Advertisement